GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

27 Jan 2014 14:00

RNS Number : 5936Y
ViaLogy PLC
27 January 2014
 



ViaLogy plc ("ViaLogy" or "the Company")

 

Result of General Meeting

 

ViaLogy is pleased to announce that at a General Meeting of the Company held earlier today, all resolutions were duly passed.

 

Further to the announcements of 7 January 2014 and 24 January 2014, ViaLogy has raised, via a Placing of 1,100,000,000 Ordinary Shares at 0.1p per share, £1.1 million (before expenses), and an additional £519,820 via an oversubscribed Open Offer to existing shareholders through the issue of 519,820,122 Ordinary Shares at 0.1p per share.

 

The Open Offer and Placing have therefore raised a total of £1,619,820 (before expenses). Application has been made for the admission of 1,649,820,122* Ordinary Shares of 0.1p each (following the Capital Reorganisation) to trading on AIM ("Admission") and dealings are expected to commence in these new shares on Tuesday 28 January 2014.

 

Following Admission, the Company shall have 2,689,460,366 ordinary shares of 0.1p in issue, which figure may be used after Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

Following their participation in the Placing and Open Offer, the following Directors of ViaLogy have an interest in the Ordinary Share Capital of the Company as follows:

 

Director

Current Holding

Placing Participation

Open Offer Entitlement

Total Holding

% Holding

Adam Reynolds

Nil

75,000,000

Nil

75,000,000

2.79

Dr. Robert Dean

2,897,304

Nil

1,448,652

4,345,956

0.17

Dr. Sandeep Gulati

6,904,412

Nil

3,912,184

10,816,596

0.41

Nicholas Mustoe

Nil

150,000,000

Nil

150,000,000

5.58

 

Capitalised terms used in this announcement are as defined in the shareholder circular dated 7 January 2014.

 

*includes 30,000,000 ordinary shares of 0.1peach being issued as part consideration for fees relating to Corporate Finance advice

 

For further information:

 

ViaLogy PLC

Mark Collingbourne mark.collingbourne@vialogy.com

 

Nominated Advisor to ViaLogy PLC (Cantor Fitzgerald Europe)

Mark Percy / Catherine Leftley - Corporate Finance +44 (0) 207 894 7000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMBXGDBUSDBGSR
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.